An electrical test laboratory's documented scope matters more than its marketing page. For medical device teams preparing an FDA premarket submission, the Accreditation Scheme for Conformity Assessment (ASCA) database provides a direct way to verify whether a lab can test to the exact standard and edition that applies to a device. The FDA-accredited testing laboratory page lists each lab's recognized standards, accreditation dates, applied U.S. national differences, and explicit clause exclusions [1]. A manufacturer reviewing these entries should treat exclusions as binding constraints rather than minor footnotes. For example, an IEC 61010-1 scope may exclude comparative tracking index, fluid pressure and leakage, ionizing radiation, microwave radiation, ultrasonic pressure, and laser radiation subclauses [1]. A lab that cannot run a required clause cannot produce a complete ASCA test report for that product, regardless of its general electrical safety credentials.

What the ASCA Database Actually Records

ASCA-accredited laboratories perform testing under ISO/IEC 17025:2017 plus ASCA program specifications tied to each eligible standard and test method [2]. The accreditation scope is not a broad endorsement. The FDA page notes that labs should demonstrate accreditation to the currently FDA-recognized versions of standards included in the program, and the scope should clearly list exclusions down to specific clauses [1][2]. This means two labs both claiming IEC 60601-1 capability may hold materially different authorizations.

One documented example is Nemko USA Inc. (Austin TL), accredited by ANAB with a start date of February 26, 2024 [3]. Its listed scope includes IEC 60601-2-34 for invasive blood pressure monitoring equipment, IEC 60601-2-22 for laser equipment, IEC 60601-1-11 for home healthcare environments, IEC 61010-1, ANSI/AAMI ES60601-1, and IEC 60601-1 Edition 3.2 [3]. Such granularity lets a manufacturer confirm that the lab's authority extends to the particular standard for its device class, not just to the general safety standard.

Reading Exclusions as Design Constraints

Exclusion lists are the most practical part of an accreditation scope. A2LA certificate 0591.09 for Eurofins Electrical and Electronic Testing NA, Inc. lists IEC/AAMI/CSA 60601-1 exclusions including resistance to environmental stress, material groups classification, cathode ray tubes, hydraulic pressure, X-radiation, microwave radiation, spark ignition, flammability, sterilization other than autoclave, positive temperature coefficient component, lithium battery, Annex G flammable anaesthetic mixtures, and Annex L insulated winding wires [8]. A device relying on a lithium battery test or a flammability clause would exceed this lab's recognized scope.

The same certificate records exclusions for IEC 60601-2-2 related to thermal performance and contact clauses, and separate exclusions under IEC/UL/CSA 62368-1 and IEC 60825-1 [8]. The pattern illustrates why manufacturers cannot assume that familiarity with a standard family means capability across every clause. The FDA process expects the accreditation body's scope to list such exclusions explicitly, which gives device teams a checklist to compare against their own product architecture before committing to a test plan [2].

A Suggested Pre-Selection Verification Sequence

A manufacturer can use a simple four-step check before engaging a laboratory. First, list the general standard, applicable collateral standards, and any Part 2 particular standard for the device's intended use and clinical function [7]. Second, search the ASCA-accredited laboratory database for each standard designation and edition. Third, read the exclusions column against the device's components and test clauses; a lithium battery-powered home-use monitor, for example, should check that both IEC 60601-1-11 and the relevant battery clauses are within scope [3][8]. Fourth, record the lab's accreditation status and start date on the selection date, then recheck before the FDA submission package is finalized, since statuses can change [2]. This sequence treats the public database as the authoritative source rather than relying on a lab's own website claims.

U.S. National Differences and Equivalent Adoptions

A recurring confusion concerns international versus U.S. versions of standards. The FDA notes that standards such as IEC 60601-1 and IEC 61010-1 are recognized with U.S. national differences applied, and that these versions are considered equivalent to their U.S. adoptions, including ANSI/AAMI ES60601-1 and ANSI/UL 61010-1 [1]. For a laboratory listed with such standards, both the U.S. adoption and the international version are considered part of the ASCA accreditation scope [1].

This equivalence reduces duplicate testing but demands precise edition tracking. A manufacturer working to IEC 60601-1 Edition 3.2 consolidated version from August 2020 should verify that the lab's scope names that edition, not an earlier 2005 adoption. The Nemko entry separately identifies ANSI/AAMI ES60601-1:2005 with amendments and IEC 60601-1 Edition 3.2, indicating that edition-specific listing remains the operative unit of accreditation [3]. A gap between the manufacturer's declared edition and the lab's listed edition can invalidate the ASCA justification.

Withdrawal Status and Maintenance Risk

Accreditation is not permanent. The FDA updated the ASCA-accredited laboratory database in September 2025 to flag certain labs as having an 'FDA Initiated Withdrawal' status, meaning their ASCA Summary Test Reports will no longer be accepted [2]. During audits, the FDA determined that those labs did not meet requirements outlined in Section 514(d) of the Federal Food, Drug, and Cosmetic Act [2]. A manufacturer that selects a lab without checking its current status may discover the problem only after testing is complete.

The withdrawal example changes how teams should evaluate laboratory stability. A marketing statement about ASCA accreditation in general does not substitute for checking the live database entry on the date of selection and again before submission. The practical rule is to confirm three items: the lab's current accreditation status, the exact standard edition in scope, and any clause exclusions relevant to the device. The FDA directs additional questions to ASCA@fda.hhs.gov, which also accepts accreditation application documents and issue reports [2].